Moreover, Rahmani and colleagues, recently demonstrated that NVP-BEZ235 in combination with the HDACi panobinostat markedly potentiates HDAC inhibitor activity in DLBCL cells, including in poor-prognosis ABC- and double-hit subtype in vitro and induced tumor regressions in DLBCL xenograft models [597]. This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.